NewEdge Advisors’s Ovid Therapeutics OVID Stock Holding History

NewEdge Advisors’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4	Closed	-$1	–	4113
2025 Q1	$1	Buy	+4	New	+$2	﹤0.01%	3949

Other funds holding OVID

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

NewEdge Advisors's OVID Position: Q2 2025 in Review

NewEdge Advisors sold out of Ovid Therapeutics (OVID) in Q2 2025, closing a stake of 4 shares — an estimated $1 sold.

NewEdge Advisors first reported a position in OVID in Q1 2025 and held it in 1 quarter. The position peaked at $1 in Q1 2025. 71 funds tracked by Wall St. Rank hold OVID as of Q2 2025.

NewEdge Advisors reported no remaining Ovid Therapeutics position as of Q2 2025 after selling out during the quarter.
NewEdge Advisors sold 4 Ovid Therapeutics shares in Q2 2025, an estimated $1.
NewEdge Advisors first reported a position in Ovid Therapeutics in Q1 2025 and held it in 1 quarter.
NewEdge Advisors's Ovid Therapeutics position peaked at $1 in Q1 2025.
71 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2025.

Based on NewEdge Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.